PropThink: BioCryst, Presidio Merger Creates Yet Another Competitor in the HCV Segment

PropThink: BioCryst, Presidio Merger Creates Yet Another Competitor in the HCV Segment

[ACN Newswire] – By Jake KingIn an all-stock merger announced Thursday morning, BioCryst Pharmaceuticals (NASDAQ:BCRX) will acquire privately-held Presidio, Inc, creating a new business entity to focus on oral Hepatitis … more

View todays social media effects on BCRX

View the latest stocks trending across Twitter. Click to view dashboard

Share this post